Study links GLP-1 drugs to higher hypotension risk

A new study has identified a potential safety concern for patients taking popular GLP-1 medications for diabetes and obesity, finding an increased risk of dangerous drops in blood pressure, particularly for older adults and those with diabetes. The research, presented at the ENDO 2026 annual meeting, analyzed health records of over 42,000 adults who were already on at least two blood pressure medications when they began treatment with drugs like semaglutide, tirzepatide, or liraglutide.

The analysis found that within six months of starting a GLP-1 drug, the rate of hypotensive events-including dizziness, fainting, falls, and clinically low blood pressure readings-increased from 8.7% to 10.2%. The elevated risk persisted at 12 months, rising from 13.6% to 14.3%. The consequences of such episodes can be severe, leading to falls, fractures, car accidents, or head injuries.

Senior author Dr. Micah Eimer, a cardiologist at Northwestern Medicine, said the study was prompted by his clinical observation of patients on GLP-1s complaining of lightheadedness and fainting. He emphasized that while the drugs are highly beneficial, this side effect is a significant concern. "Hypotension is...